Blakeley Jaishri O, Llinas Rafael H
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
J Neurol Sci. 2007 Oct 15;261(1-2):55-62. doi: 10.1016/j.jns.2007.04.031. Epub 2007 Jul 5.
The treatment of acute stroke changed dramatically since the publication of the NINDS trail for IV rt-PA for acute stroke. While this was not the first trial, it was the first positive trial. Subsequently there has been an explosion in acute treatment modalities since the NINDS trial showed that acute stroke treatment is feasible. The following chapter reviews the thrombolysis trials, the inclusion and exclusion criteria of intravenous and intra-arterial use of pharmacologic and mechanical thrombolysis in acute ischemic stroke. Also discussed are the new pharmacotherapies and mechanical devices that will hopefully expand the treatment window and make thrombolysis safer and more effective.
自美国国立神经疾病与中风研究所（NINDS）关于急性中风静脉注射重组组织型纤溶酶原激活剂（IV rt-PA）的试验结果发表以来，急性中风的治疗发生了巨大变化。虽然这不是首个此类试验，但却是首个呈阳性结果的试验。自NINDS试验表明急性中风治疗可行之后，急性治疗方式便如雨后春笋般涌现。以下章节回顾了溶栓试验、急性缺血性中风静脉及动脉使用药物和机械溶栓的纳入与排除标准。还讨论了有望扩大治疗窗并使溶栓更安全、有效的新药物疗法和机械设备。
